{
    "info": {
        "nct_id": "NCT03943004",
        "official_title": "A Phase I Study of DFP-14927 in Patients With Advanced Solid Tumors",
        "inclusion_criteria": "1. Patients must have histologically (or cytologically) confirmed diagnosis of solid tumor, refractory after standard therapy for the disease or for which conventional systemic therapy is not reliably effective or no effective therapy is available. Note: For expansion cohorts patients must have histologically (or cytologically) confirmed diagnosis of gastroesophageal cancer, pancreatic cancer, or cholangiocarcinoma that has relapsed or is refractory to standard therapy.\n2. Aged ≥ 18 years.\n3. ECOG Performance Status of 0 or 1.\n4. Adequate clinical laboratory values defined as:\n\n   1. absolute neutrophil count ≥ 1.5 x 10⁹/L\n   2. platelets ≥ 100 x 10⁹/L\n   3. hemoglobin ≥ 9.0 g/dL (transfusions permissible)\n   4. plasma creatinine ≤ 1.5 x upper limit of normal (ULN) for the institution or calculated clearance ≥ 60 mL/min (Cockcroft-Gault formula)\n   5. total bilirubin ≤ 1.5 x ULN\n   6. alanine transaminase (ALT) and aspartate transaminase (AST) < 2.5 x ULN (<5 x ULN if documented hepatic metastases)\n   7. prothrombin time (PT) ≤1.2 x ULN, partial thromboplastin time (PTT) ≤ 1.2 ULN, and international normalized ratio (INR) ≤ 1.5\n5. Absence of uncontrolled intercurrent illnesses, including uncontrolled infections, cardiac conditions, uncontrolled diabetes mellitus, or other organ dysfunctions.\n6. Patients may have measurable or non-measurable disease as defined by RECIST 1.1.\n7. Signed Informed-consent prior to the start of any study specific procedures.\n8. Women of child-bearing potential must have a negative serum or urine pregnancy test. Male and female patients must agree to use acceptable contraceptive methods for the duration of the study and for at least one month after the last drug administration.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Patients will be excluded if they have received previous chemotherapy, immunotherapy, radiotherapy or any other investigational therapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) or 5 half-lives for targeted therapies prior to this study entry.\n2. Have not recovered from adverse events (must be Grade ≤1) due to agents administered more than 4 weeks earlier.\n3. Have had any major bleeding episodes (variceal bleeds, hemorrhagic strokes, internal abdominal bleeds, etc.) within 6 months prior to starting study drug.\n4. Known hypersensitivity to any study drug component (such as pegylated medications).\n5. Extensive prior radiotherapy, more than 30% of bone marrow reserves, or prior bone marrow/stem cell transplantation.\n6. Any concomitant condition that in the opinion of the investigator could compromise the objectives of this study and the patient's compliance.\n7. Pregnant or lactating individuals.\n8. Current malignancies of another type, with the exception of adequately treated in situ cervical cancer and basal cell skin cancer or other malignancies with no evidence of disease for 2 years or more.\n9. Known history of HIV, HBV or HCV infection.\n10. Documented or known bleeding disorder.\n11. Requirement for anticoagulation treatment that increases INR or aPTT above the normal range (low dose DVT or line prophylaxis is allowed).\n12. Clinically evident CNS metastases or leptomeningeal disease not controlled by prior surgery or radiotherapy; history of seizure disorder not controlled by anti-seizure medication at the time of enrollment. Patients with primary CNS malignancies are excluded.\n13. Patients with a significant cardiovascular disease or condition, including:\n\n    1. Myocardial infarction within 6 months of study entry\n    2. NYHA Class III or IV heart failure\n    3. Uncontrolled dysrhythmias or poorly controlled angina.\n    4. History of serious ventricular arrhythmia (VT or VF, ≥ 3 beats in a row) and/or risk factors (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)\n    5. Baseline prolongation of QT/QTc interval (repeated demonstration of QTc ≥ 450 msec for men and 470 msec for women). QTc values up to 500 msec will be acceptable where patient's medical history, e.g. bundle branch block, is known to cause mild QTc prolongation and the condition is well controlled",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "4. Adequate clinical laboratory values defined as:",
            "criterions": [
                {
                    "exact_snippets": "Adequate clinical laboratory values",
                    "criterion": "clinical laboratory values",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Signed Informed-consent prior to the start of any study specific procedures.",
            "criterions": [
                {
                    "exact_snippets": "Signed Informed-consent prior to the start of any study specific procedures.",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to the start of any study specific procedures"
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. plasma creatinine ≤ 1.5 x upper limit of normal (ULN) for the institution or calculated clearance ≥ 60 mL/min (Cockcroft-Gault formula)",
            "criterions": [
                {
                    "exact_snippets": "plasma creatinine ≤ 1.5 x upper limit of normal (ULN) for the institution",
                    "criterion": "plasma creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "calculated clearance ≥ 60 mL/min (Cockcroft-Gault formula)",
                    "criterion": "creatinine clearance (Cockcroft-Gault formula)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "mL/min"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. prothrombin time (PT) ≤1.2 x ULN, partial thromboplastin time (PTT) ≤ 1.2 ULN, and international normalized ratio (INR) ≤ 1.5",
            "criterions": [
                {
                    "exact_snippets": "prothrombin time (PT) ≤1.2 x ULN",
                    "criterion": "prothrombin time (PT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.2,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "partial thromboplastin time (PTT) ≤ 1.2 ULN",
                    "criterion": "partial thromboplastin time (PTT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.2,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "international normalized ratio (INR) ≤ 1.5",
                    "criterion": "international normalized ratio (INR)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": ""
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Aged ≥ 18 years.",
            "criterions": [
                {
                    "exact_snippets": "Aged ≥ 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Patients may have measurable or non-measurable disease as defined by RECIST 1.1.",
            "criterions": [
                {
                    "exact_snippets": "measurable or non-measurable disease as defined by RECIST 1.1",
                    "criterion": "disease measurability (RECIST 1.1)",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": [
                                "measurable",
                                "non-measurable"
                            ]
                        },
                        {
                            "requirement_type": "definition standard",
                            "expected_value": "RECIST 1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. total bilirubin ≤ 1.5 x ULN",
            "criterions": [
                {
                    "exact_snippets": "total bilirubin ≤ 1.5 x ULN",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. hemoglobin ≥ 9.0 g/dL (transfusions permissible)",
            "criterions": [
                {
                    "exact_snippets": "hemoglobin ≥ 9.0 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9.0,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. ECOG Performance Status of 0 or 1.",
            "criterions": [
                {
                    "exact_snippets": "ECOG Performance Status of 0 or 1",
                    "criterion": "ECOG Performance Status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Women of child-bearing potential must have a negative serum or urine pregnancy test. Male and female patients must agree to use acceptable contraceptive methods for the duration of the study and for at least one month after the last drug administration.",
            "criterions": [
                {
                    "exact_snippets": "Women of child-bearing potential must have a negative serum or urine pregnancy test",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "test type",
                            "expected_value": [
                                "serum pregnancy test",
                                "urine pregnancy test"
                            ]
                        },
                        {
                            "requirement_type": "applicability",
                            "expected_value": "women of child-bearing potential"
                        }
                    ]
                },
                {
                    "exact_snippets": "Male and female patients must agree to use acceptable contraceptive methods for the duration of the study and for at least one month after the last drug administration",
                    "criterion": "contraceptive use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "method",
                            "expected_value": "acceptable contraceptive methods"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "for the duration of the study and for at least one month after the last drug administration"
                        },
                        {
                            "requirement_type": "applicability",
                            "expected_value": [
                                "male patients",
                                "female patients"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Absence of uncontrolled intercurrent illnesses, including uncontrolled infections, cardiac conditions, uncontrolled diabetes mellitus, or other organ dysfunctions.",
            "criterions": [
                {
                    "exact_snippets": "Absence of uncontrolled intercurrent illnesses",
                    "criterion": "uncontrolled intercurrent illnesses",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled infections",
                    "criterion": "uncontrolled infections",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "cardiac conditions",
                    "criterion": "uncontrolled cardiac conditions",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled diabetes mellitus",
                    "criterion": "uncontrolled diabetes mellitus",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "other organ dysfunctions",
                    "criterion": "uncontrolled organ dysfunctions",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. absolute neutrophil count ≥ 1.5 x 10⁹/L",
            "criterions": [
                {
                    "exact_snippets": "absolute neutrophil count ≥ 1.5 x 10⁹/L",
                    "criterion": "absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "x 10⁹/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. platelets ≥ 100 x 10⁹/L",
            "criterions": [
                {
                    "exact_snippets": "platelets ≥ 100 x 10⁹/L",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "x 10⁹/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Patients must have histologically (or cytologically) confirmed diagnosis of solid tumor, refractory after standard therapy for the disease or for which conventional systemic therapy is not reliably effective or no effective therapy is available. Note: For expansion cohorts patients must have histologically (or cytologically) confirmed diagnosis of gastroesophageal cancer, pancreatic cancer, or cholangiocarcinoma that has relapsed or is refractory to standard therapy.",
            "criterions": [
                {
                    "exact_snippets": "histologically (or cytologically) confirmed diagnosis of solid tumor",
                    "criterion": "solid tumor diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histology",
                                "cytology"
                            ]
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "refractory after standard therapy for the disease or for which conventional systemic therapy is not reliably effective or no effective therapy is available",
                    "criterion": "response to standard therapy",
                    "requirements": [
                        {
                            "requirement_type": "refractory to standard therapy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "conventional systemic therapy effectiveness",
                            "expected_value": "not reliably effective"
                        },
                        {
                            "requirement_type": "availability of effective therapy",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "For expansion cohorts patients must have histologically (or cytologically) confirmed diagnosis of gastroesophageal cancer, pancreatic cancer, or cholangiocarcinoma that has relapsed or is refractory to standard therapy",
                    "criterion": "specific cancer type for expansion cohorts",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": [
                                "gastroesophageal cancer",
                                "pancreatic cancer",
                                "cholangiocarcinoma"
                            ]
                        },
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histology",
                                "cytology"
                            ]
                        },
                        {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "relapsed",
                                "refractory to standard therapy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "1. Myocardial infarction within 6 months of study entry",
            "criterions": [
                {
                    "exact_snippets": "Myocardial infarction within 6 months of study entry",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Any concomitant condition that in the opinion of the investigator could compromise the objectives of this study and the patient's compliance.",
            "criterions": [
                {
                    "exact_snippets": "Any concomitant condition that in the opinion of the investigator could compromise the objectives of this study and the patient's compliance.",
                    "criterion": "concomitant condition",
                    "requirements": [
                        {
                            "requirement_type": "potential to compromise study objectives or patient compliance (as judged by investigator)",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Patients with a significant cardiovascular disease or condition, including:",
            "criterions": [
                {
                    "exact_snippets": "significant cardiovascular disease or condition",
                    "criterion": "cardiovascular disease or condition",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Have had any major bleeding episodes (variceal bleeds, hemorrhagic strokes, internal abdominal bleeds, etc.) within 6 months prior to starting study drug.",
            "criterions": [
                {
                    "exact_snippets": "major bleeding episodes (variceal bleeds, hemorrhagic strokes, internal abdominal bleeds, etc.) within 6 months prior to starting study drug",
                    "criterion": "major bleeding episodes",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Known hypersensitivity to any study drug component (such as pegylated medications).",
            "criterions": [
                {
                    "exact_snippets": "Known hypersensitivity to any study drug component (such as pegylated medications)",
                    "criterion": "hypersensitivity to study drug component",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Requirement for anticoagulation treatment that increases INR or aPTT above the normal range (low dose DVT or line prophylaxis is allowed).",
            "criterions": [
                {
                    "exact_snippets": "Requirement for anticoagulation treatment that increases INR or aPTT above the normal range",
                    "criterion": "anticoagulation treatment",
                    "requirements": [
                        {
                            "requirement_type": "necessity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "effect on INR",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "normal range"
                            }
                        },
                        {
                            "requirement_type": "effect on aPTT",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "normal range"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "low dose DVT or line prophylaxis is allowed",
                    "criterion": "low dose DVT or line prophylaxis",
                    "requirements": [
                        {
                            "requirement_type": "allowance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Uncontrolled dysrhythmias or poorly controlled angina.",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled dysrhythmias",
                    "criterion": "dysrhythmias",
                    "requirements": [
                        {
                            "requirement_type": "control",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "poorly controlled angina",
                    "criterion": "angina",
                    "requirements": [
                        {
                            "requirement_type": "control",
                            "expected_value": "poorly controlled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. NYHA Class III or IV heart failure",
            "criterions": [
                {
                    "exact_snippets": "NYHA Class III or IV heart failure",
                    "criterion": "heart failure (NYHA class)",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "Class III",
                                "Class IV"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Current malignancies of another type, with the exception of adequately treated in situ cervical cancer and basal cell skin cancer or other malignancies with no evidence of disease for 2 years or more.",
            "criterions": [
                {
                    "exact_snippets": "Current malignancies of another type",
                    "criterion": "malignancy of another type",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "with the exception of adequately treated in situ cervical cancer and basal cell skin cancer",
                    "criterion": "adequately treated in situ cervical cancer or basal cell skin cancer",
                    "requirements": [
                        {
                            "requirement_type": "exception",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "other malignancies with no evidence of disease for 2 years or more",
                    "criterion": "other malignancies with no evidence of disease",
                    "requirements": [
                        {
                            "requirement_type": "disease-free duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Extensive prior radiotherapy, more than 30% of bone marrow reserves, or prior bone marrow/stem cell transplantation.",
            "criterions": [
                {
                    "exact_snippets": "Extensive prior radiotherapy",
                    "criterion": "prior radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "extent",
                            "expected_value": "extensive"
                        }
                    ]
                },
                {
                    "exact_snippets": "more than 30% of bone marrow reserves",
                    "criterion": "bone marrow reserves exposed to prior radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "exposure_percentage",
                            "expected_value": {
                                "operator": ">",
                                "value": 30,
                                "unit": "%"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "prior bone marrow/stem cell transplantation",
                    "criterion": "prior bone marrow or stem cell transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Baseline prolongation of QT/QTc interval (repeated demonstration of QTc ≥ 450 msec for men and 470 msec for women). QTc values up to 500 msec will be acceptable where patient's medical history, e.g. bundle branch block, is known to cause mild QTc prolongation and the condition is well controlled",
            "criterions": [
                {
                    "exact_snippets": "Baseline prolongation of QT/QTc interval (repeated demonstration of QTc ≥ 450 msec for men and 470 msec for women)",
                    "criterion": "QTc interval",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 450,
                                        "unit": "msec"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "sex",
                            "expected_value": "male"
                        }
                    ]
                },
                {
                    "exact_snippets": "Baseline prolongation of QT/QTc interval (repeated demonstration of QTc ≥ 450 msec for men and 470 msec for women)",
                    "criterion": "QTc interval",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 470,
                                        "unit": "msec"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        }
                    ]
                },
                {
                    "exact_snippets": "QTc values up to 500 msec will be acceptable where patient's medical history, e.g. bundle branch block, is known to cause mild QTc prolongation and the condition is well controlled",
                    "criterion": "QTc interval",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 500,
                                        "unit": "msec"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "medical history",
                            "expected_value": "bundle branch block"
                        },
                        {
                            "requirement_type": "condition control",
                            "expected_value": "well controlled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Documented or known bleeding disorder.",
            "criterions": [
                {
                    "exact_snippets": "Documented or known bleeding disorder",
                    "criterion": "bleeding disorder",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. History of serious ventricular arrhythmia (VT or VF, ≥ 3 beats in a row) and/or risk factors (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)",
            "criterions": [
                {
                    "exact_snippets": "History of serious ventricular arrhythmia (VT or VF, ≥ 3 beats in a row)",
                    "criterion": "serious ventricular arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "ventricular tachycardia (VT)",
                                "ventricular fibrillation (VF)"
                            ]
                        },
                        {
                            "requirement_type": "episode_length",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "beats in a row"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "risk factors (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)",
                    "criterion": "risk factors for ventricular arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "examples",
                            "expected_value": [
                                "heart failure",
                                "hypokalemia",
                                "family history of Long QT Syndrome"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Have not recovered from adverse events (must be Grade ≤1) due to agents administered more than 4 weeks earlier.",
            "criterions": [
                {
                    "exact_snippets": "Have not recovered from adverse events (must be Grade ≤1)",
                    "criterion": "adverse events",
                    "requirements": [
                        {
                            "requirement_type": "recovery status",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity grade",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "Grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "agents administered more than 4 weeks earlier",
                    "criterion": "time since prior agent administration",
                    "requirements": [
                        {
                            "requirement_type": "elapsed time",
                            "expected_value": {
                                "operator": ">",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Pregnant or lactating individuals.",
            "criterions": [
                {
                    "exact_snippets": "Pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "lactating",
                    "criterion": "lactation status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Clinically evident CNS metastases or leptomeningeal disease not controlled by prior surgery or radiotherapy; history of seizure disorder not controlled by anti-seizure medication at the time of enrollment. Patients with primary CNS malignancies are excluded.",
            "criterions": [
                {
                    "exact_snippets": "Clinically evident CNS metastases or leptomeningeal disease not controlled by prior surgery or radiotherapy",
                    "criterion": "CNS metastases or leptomeningeal disease",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "not controlled by prior surgery or radiotherapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "history of seizure disorder not controlled by anti-seizure medication at the time of enrollment",
                    "criterion": "seizure disorder",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "not controlled by anti-seizure medication at the time of enrollment"
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with primary CNS malignancies are excluded",
                    "criterion": "primary CNS malignancies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "6. alanine transaminase (ALT) and aspartate transaminase (AST) < 2.5 x ULN (<5 x ULN if documented hepatic metastases)",
            "criterions": [
                {
                    "exact_snippets": "alanine transaminase (ALT) < 2.5 x ULN (<5 x ULN if documented hepatic metastases)",
                    "criterion": "alanine transaminase (ALT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 2.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (if documented hepatic metastases)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "aspartate transaminase (AST) < 2.5 x ULN (<5 x ULN if documented hepatic metastases)",
                    "criterion": "aspartate transaminase (AST)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 2.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (if documented hepatic metastases)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [
        {
            "line": "1. Patients will be excluded if they have received previous chemotherapy, immunotherapy, radiotherapy or any other investigational therapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) or 5 half-lives for targeted therapies prior to this study entry.",
            "criterions": [
                {
                    "exact_snippets": "received previous chemotherapy ... within 4 weeks",
                    "criterion": "previous chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "received previous immunotherapy ... within 4 weeks",
                    "criterion": "previous immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "received previous radiotherapy ... within 4 weeks",
                    "criterion": "previous radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "received ... any other investigational therapy within 4 weeks",
                    "criterion": "previous investigational therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "6 weeks for nitrosoureas or mitomycin C",
                    "criterion": "previous nitrosoureas or mitomycin C therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "5 half-lives for targeted therapies",
                    "criterion": "previous targeted therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "half-lives"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Known history of HIV, HBV or HCV infection.",
            "criterions": [
                {
                    "exact_snippets": "Known history of HIV",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known history of HBV",
                    "criterion": "HBV infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known history of ... HCV infection",
                    "criterion": "HCV infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}